Dr. Wang on Genomic Analysis of Breast Cancer Risk in Pediatric Cancer Survivors

Zhaoming Wang, PhD
Published: Tuesday, Aug 28, 2018



Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses a genomic analysis of breast cancer risk in pediatric cancer survivors.

Researchers did a genomic sequencing assessment on 3000 pediatric cancer survivors, analyzing the pathogenesis of the patients’ germline mutations. The goal was to determine the genomic contribution to the risk of subsequent breast cancer. Preclinical data suggested that the exposure of radiation to the breast tissue during the treatment of pediatric cancer is a major risk factor. Wang adds that literature had also been published indicating that certain chemotherapy agents contributed to increased risk. Genetic risk is currently unknown, Wang says.

Typical clinical demographics were used in the analysis, Wang says, and genomic expressions were factored in. He presented the findings at the 2018 AACR Annual Meeting.
SELECTED
LANGUAGE


Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses a genomic analysis of breast cancer risk in pediatric cancer survivors.

Researchers did a genomic sequencing assessment on 3000 pediatric cancer survivors, analyzing the pathogenesis of the patients’ germline mutations. The goal was to determine the genomic contribution to the risk of subsequent breast cancer. Preclinical data suggested that the exposure of radiation to the breast tissue during the treatment of pediatric cancer is a major risk factor. Wang adds that literature had also been published indicating that certain chemotherapy agents contributed to increased risk. Genetic risk is currently unknown, Wang says.

Typical clinical demographics were used in the analysis, Wang says, and genomic expressions were factored in. He presented the findings at the 2018 AACR Annual Meeting.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x